ATE Stock Overview
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally.
Antibe Therapeutics Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.60|
|52 Week High||CA$1.25|
|52 Week Low||CA$0.56|
|1 Month Change||-4.76%|
|3 Month Change||0%|
|1 Year Change||-51.61%|
|3 Year Change||-84.62%|
|5 Year Change||-25.00%|
|Change since IPO||-89.09%|
Recent News & Updates
|ATE||CA Pharmaceuticals||CA Market|
Return vs Industry: ATE exceeded the Canadian Pharmaceuticals industry which returned -67.8% over the past year.
Return vs Market: ATE underperformed the Canadian Market which returned -8.4% over the past year.
|ATE Average Weekly Movement||6.0%|
|Pharmaceuticals Industry Average Movement||11.8%|
|Market Average Movement||9.8%|
|10% most volatile stocks in CA Market||18.1%|
|10% least volatile stocks in CA Market||3.8%|
Stable Share Price: ATE is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ATE's weekly volatility (6%) has been stable over the past year.
About the Company
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company’s drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study.
Antibe Therapeutics Inc. Fundamentals Summary
|ATE fundamental statistics|
Is ATE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATE income statement (TTM)|
|Cost of Revenue||CA$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.47|
|Net Profit Margin||0.00%|
How did ATE perform over the long term?See historical performance and comparison